We will help you navigate through the challenges of reimbursement and funding for medical devices and in-vitro diagnostics in Europe

MTRC is an ISO 9001:2015 certified provider of Pan-European reimbursement services and products for Med Tech and IVD industry

MTRC is a unique provider of Pan-European reimbursement services and products for Med Tech and IVD industry

Scope

Coding, payment mechanism, reimbursement tariffs, the pathway to create or improve reimbursement situation

 

Project-based on-demand work or >48 off-the-shelf syndicated reports

Countries
19 EU + Canada
Availability
Mixed
Scope

Seminars on introduction into market access for medical devices and IVD tests, seminars on reimbursement systems in individual countries (>70 reports)

 

Syndicated analytical reports on the topics of HTA, innovation funding, reimbursement of health apps

Countries
19 EU
Availability
Off-the-shelf
Scope

Subscription service with email alerts about initiated or published health technology assessments and reimbursement decisions for medical devices and in-vitro diagnostic tests from reimbursement (EU) and HTA (global) organizations

Countries
36 countries globally
Availability
On-demand
Scope

Development of health economic models for medical devices and IVD tests in European countries. Development of de novo and adaptation of existing models to new countries. Publication of results in peer-reviewed journals

Countries
EU and the US
Availability
On-demand
Scope

Development of systematic literature reviews and meta-analyses. Publication of results in peer-reviewed journals. Development of early and comprehensive value dossiers to support market access activities

Countries
EU and global
Availability
On-demand

Why us?

Analyses from the same vendor for 34 different EU countries
Analyses from the same vendor for 34 different EU countries

Save money and time, get standardized analysis. One of the broadest coverage of EU markets. Our key value proposition is provision of high quality pan-European support

Pharma approach is put aside
Pharma approach is put aside

Work with a company truly specialized in medical devices and diagnostics. Benefit from our topical knowledge from hundreds of projects

Getting results instantly (reports) or within 4-8 weeks (services)
Getting results instantly (reports) or within 4-8 weeks (services)

Make business decisions quickly

17 out of top-30 companies choose MTRC for reimbursement support
17 out of top-30 companies choose MTRC for reimbursement support

Work with a provider who understands the industry’s needs. We served more than 150 clients over the last six years

More than 700 accomplished projects since 2017
More than 700 accomplished projects since 2017

Work with a provider who has experience in your field. We are ISO 9001:2015 certified and pay a lot of attention to maintain a good quality of services, including >300 internal instructions, regular quality management meetings, strict onboarding and training procedures

Team of 20 full-time employees in 6 countries
Team of 20 full-time employees in 6 countries

Unlike companies with an affiliate model, we do most services with in-house analysts ensuring greater quality, lower cost and predictable outcomes

MTRC is a thought leader in the field of European Med Tech reimbursement
MTRC is a thought leader in the field of European Med Tech reimbursement

MTRC has unique insights into market access through its various activities, including annual syndicated reports on the topics of HTA, innovation funding, reimbursement of digital health, comprehensive newsletter services, unparalleled educational platform and others

To stay up-to-date, we daily monitor developments of reimbursement systems in Europe

Subscribe to our newsletter to get updates every 2nd week

Only less than 10% of the news is reported in the free-of-charge newsletter. Access our paid services "HTA Alerts" and "Reimbursement Alerts" to get full, personalized reports from more than 90 reimbursement and HTA organizations in EU and globally. Request a three-month, free, no-obligation trial to understand the value to your organization

04 Oct 2022
A value dossier is a document of a certain structure that summarizes in a comprehensive and unbiased way all value-related messages for medical technology. The unique approach of MTRC is based on a deep understanding of evidence and data presentation requirements for market access processes in a large number of European countries.

08

Jun 2023

In the period of April-May 2023, the Galician Agency for Health Technology Assessment (AVALIA-T) initiated the five health technology assessments referred to IVD, nephrology and urology, obstetrics and gynecology, pulmonary and airways as well as surgical procedures technology groups. The assessments on stereotactic virtual navigation system for percutaneous puncture as well as tumor ablation and invasive telemonitoring of pulmonary pressure in patients with heart failure were released.

07

Jun 2023

In May 2023, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedure Guidance (intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries), two new Diagnostic Guidance (MRI fusion biopsy systems for diagnosing prostate cancer, automated ankle-brachial pressure index measurement devices to detect peripheral arterial disease), and three new Health Technology Evaluations (Digitally enabled therapies for adults with anxiety disorders / with depression, and point-of-care tests for urinary tract infections). Also, four clinical guidelines were updated.

07

Jun 2023

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Lavaste investigated the relationship between primary care provision and the uptake of voluntary private health insurance (VPHI) in Finland. By analyzing the data obtained from the national registry and incorporating data on healthcare provider proximity and reimbursement fees, the study reveals that sociodemographic factors (employment, levels of income and education) and patients’ preference are key factors in VPHI uptake and not the (dis)satisfaction with the care provision in public settings. Furthermore, proximity to private (but not public) healthcare providers supports VPHI uptake.

06

Jun 2023

Director of MTRC Oleg Borisenko participated in the session “Innovative Payment Schemes (IPSs) in Europe: springboard for innovation?” at the Med Tech Forum in Dublin on the 31st of May 2023. The section was moderated by Rachele Busca (Director, HTA and Real-World Evidence, EMEACLA, Edwards Lifesciences) and panelists included Daniel Bamford (Deputy Director, Medtech and Digital, Innovation, Research and Life Sciences, NHS England) and Louisa Stüwe (Ministerial eHealth Delegation, Ministry of Health and Prevention, France). Oleg presented the summary of the report on innovative payment schemes for medical technologies, commissioned in 2022 by the European industry association Med Tech Europe to MTRC. We present a summary of the presentation.

Our two core services are the provision of off-the-shelf and on-demand reimbursement analysis and the development of reimbursement strategy for medical devices in 19 European countries + Australia and Canada

Analysis

Reimbursement

  • Availability of procedure / reimbursement code
  • Reimbursement mechanism (diagnosis-related group or fee for service)
  • Availability of add-on reimbursement
  • Availability of innovation funding
  • Reimbursement tariffs

National funding

Willingness to pay for technology, based on:

  • Statements from national commissioners (e.g., NHS England)
  • Health Benefit Catalogues (e.g. in Spain, LEA Levels in Italy)
  • National clinical guidance (e.g. NICE in the UK, Haute Autorité de Santé in France, Socialstyrelsen in Sweden)
  • National health technology assessments in connection with reimbursement decisions (e.g. NICE for Technology Appraisal in the UK, Haute Autorité de Santé in France)
  • Specific funding frameworks (e.g., “New method” in Norway)
Strategy

Reimbursement strategy

Pathway to get reimbursement:

  • Overview of drivers and barriers for adoption
  • Overview of key reimbursement and funding pathways (including state-sponsored studies and innovation funding)
  • Detailed presentation of individual pathways (process, stakeholders, requirements, timelines)
  • Action plan

Our services cover 19 European countries, including Austria, Belgium, Czech Republic, Denmark, England, Finland, France, Germany, Hungary, Italy, the Netherlands, Norway, Poland, Romania, Russia, Spain, Sweden, Switzerland and Turkey + Australia and Canada

We provide services for major types of medical technologies

Implantable devices

Interventional procedures

Non-in­ter­ven­tional procedures

In-vitro diagnostic tests

Medical aids

Our analytical team has worked on hundreds of reimbursement projects within different clinical and technological areas, including heart valve replacement, minimally invasive and open heart surgery, coronary, cerebral and peripheral stenting, coronary diagnostic and imaging techniques (fractional flow reserve, intravascular ultrasound), coronary, cerebral and peripheral vascular thrombectomy, implantable and extracorporeal ventricular assist devices, clinic- and home-based dialysis, extracorporeal membrane oxygenation, apheresis, obesity surgery, hernia and reconstruction surgery, tissue products and skin reconstruction surgery, negative wound pressure therapy and medical bandages, neurostimulators for different indications, cell therapy, rehabilitation devices, devices for minimally invasive and open spine surgery, embolization procedures, glucose monitoring, use of fusidial markers, radiotherapy, endoscopy and more

Confidence in results

MTRC is ISO 9001:2015 certified organization (with the United Kingdom Accreditation Service, UKAS). We have established numerous procedures and services to ensure the high relevance and precision of our analysis in order to successfully guide your business decisions:

  • Standard Operating Procedures and Work Instructions
  • Access to official coding and DRG manuals, tariff lists and grouping software
  • A team comprised of experienced Clinical Coders with a medical background
  • Quick access to health authorities to address uncertainties
  • Ongoing research program to get insights from payer and provider interviews
  • All reports are reviewed by the CEO before release

Check out our database of the off-the-shelf reimbursement reports for medical technologies in 11 European countries

Released reports:

  • 3D conformal radiation therapy
  • Ablation of heart tissue for atrial fibrillation
  • Angioplasty of arteries of lower extremities for peripheral artery disease
  • Atherectomy for peripheral artery disease
  • Bariatric surgery
  • Biologic and synthetic skin substitutes
  • Brachytherapy
  • Breast reconstruction
  • Capsule endoscopy
  • Cardiac pacemakers
  • Cardiac resynchronization therapy
  • Cholecystectomy
  • Coronary artery bypass grafting
  • Coronary imaging and diagnostic procedures
  • Coronary percutaneous revascularization procedures
  • Deep brain stimulation
  • Diagnostic endoscopic procedures on the lower gastrointestinal tract
  • Diagnostic endoscopic procedures on the upper gastrointestinal tract
  • Endoscopic biliary procedures
  • Health apps
  • Hemodialysis for acute kidney injury
  • Hernia repair
  • Embolic Protection Devices during percutaneous cardiac procedures (PCI and TAVI)
  • Endovascular repair (EVAR) of abdominal aortic aneurysm (AAA)
  • Extra-corporeal membrane oxygenation (ECMO) for pulmonary and cardiac failure
  • Image-guided radiotherapy
  • Implantable cardioverter defibrillators (ICDs)
  • Intensity modulated radiotherapy (IMRT)
  • Left atrial appendage occlusion
  • Mechanical ventilzation
  • Mechanical thrombectomy for acute ischemic stroke
  • Minimally-invasive endoluminal procedures for gastro-esophageal reflux disease (GERD)
  • Open replacement of heart valves (all valves)
  • Percutaneous ablation procedures for diseases of lung, prostate, kidney, liver and bone
  • Percutaneous procedures for deep vein thrombosis
  • Proton Therapy
  • Robotic surgery interventions
  • Selective internal radiation therapy (SIRT)
  • Spinal cord stimulation
  • Stereotactic body radiation therapy
  • Stereotactic Radiosurgery
  • Surgical and endovascular treatment of brain aneurysm
  • Transcatheter aortic valve implantation (TAVI)
  • Transcatheter mitral valve leaflet repair using mitral clips for mitral regurgitation
  • Use of intra-aortic balloon pump (myocardial infarction and unstable angina, complicated by cardiogenic shock)
  • Vascular access for long-term use: AV fistula and AV graft
  • Ventricular assist devices for circulatory support
  • Volumetric modulated arc therapy (VMAT)

Ongoing reports:

  • Companion diagnostic tests for breast cancer
  • Biologic and synthetic skin substitutes